Earthquake Rattles Life Sciences Companies Across Sectors; MHLW Response Could Impact Pricing And Inspections
This article was originally published in PharmAsia News
Executive Summary
TOKYO - The recent natural disasters in Japan create much uncertainty around various sectors in Japan's healthcare industry, but analysts are cautiously optimistic about most companies in the pharma, biotech, device and diagnostic industries ability to recover quickly. But these companies rely on Japan's Pharmaceuticals and Medical Devices Agency to operate in the country, and the agency's recovery and response to the crisis may have implications for price revisions and compliance inspections
You may also be interested in...
Business Continuity Vital In Japan For Companies Like Daiichi Sankyo On Slow Road To Recovery; Earthquake Impacts Organizational Moves
TOKYO - An emerging view of the damage to pharmaceutical companies in Japan points to a scenario in which affected companies must find a way to ensure business continuity while simultaneously beginning a slow recovery
Business Continuity Vital In Japan For Companies Like Daiichi Sankyo On Slow Road To Recovery; Earthquake Impacts Organizational Moves
TOKYO - An emerging view of the damage to pharmaceutical companies in Japan points to a scenario in which affected companies must find a way to ensure business continuity while simultaneously beginning a slow recovery
Southwest Japan-heavy Takeda And Dainippon Sumitomo Spared Earthquake Damage, Others May Rebound, But Tokyo Headquarters' Quieted By Rail Disruptions
TOKYO - Offices across Tokyo remained closed Tuesday, stalling the operations of headquarters for many pharma and medical device companies in Japan as the city faced train and highway closures and threats of blackouts through the rest of the week. Meanwhile, stocks for many of the Japanese pharma tumbled on the Nikkei March 14 in response to the emergency at power plants in Fukushima prefecture